{
    "title": "Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12696935/Unlike-Pfizer-Moderna-meet-2023-COVID-forecast-analysts-say.html",
    "date": "2023-11-01",
    "keywords": [
        "vaccine",
        "market",
        "pfizer",
        "covid",
        "mandowara",
        "company",
        "demand",
        "fall",
        "covid19",
        "government",
        "outlook",
        "shot",
        "analyst",
        "virus",
        "rsv",
        "latestage",
        "khushi",
        "end",
        "target",
        "year",
        "portion",
        "goal",
        "industry",
        "figure",
        "season",
        "rest",
        "forecast",
        "question",
        "month",
        "vaccination",
        "moderna",
        "amp",
        "co",
        "hartaj",
        "michael",
        "rollout",
        "thirdquarter",
        "loss",
        "charge",
        "treatment",
        "paxlovid",
        "inventory",
        "cambridge",
        "product",
        "research",
        "development",
        "rampd",
        "quarter",
        "seeks",
        "companys",
        "trial",
        "gsk",
        "study",
        "formulation",
        "september",
        "response",
        "b",
        "influenza",
        "respiratory",
        "pipeline",
        "flu",
        "stability",
        "yee",
        "reporting",
        "bengaluru",
        "wingrove",
        "yerk",
        "editing",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}